Main vaccine types and phase 3–4 candidates as of June 2021 [50]

Vaccine platform descriptionNumber of candidate vaccines%Number of dosesScheduleRoute of administrationDevelopers (Candidate vaccine type)Phase
mRNA vaccines16162Day 0 + 28i.mModerna (mRNA 1273)Phase 4*
2Day 0 + 2i.m.Pfizer/BioNTech (BNT162b2)Phase 4*
2Day 0 + 28i.m.CureVac AG (CVnCoV)Phase 3
2Day 0 + 14or Day 0 + 28i.m.Academy of MilitaryScience (AMS)/(ARCoV)Phase 3
Vectorvaccines18181–2Day 0 + 28i.m.Oxford/Astra Zeneca (ChAdOx1)Phase 4*
1Day 0i.m.CansinoBiologicalInc. (Ad5-nCoV)Phase 4
2Day 0 + 21i.m.Sputnik V (Gam-COVID-Vac) (rAd26-S+rAd5-S)Phase 3
1–2Day 0 or Day 0 + 56i.m.Johnson&Johnson/ Janssen Pharmaceutical (Ad26. COV2.S)Phase 3*
1Day 0i.m.ReiThera + Leukocare + Univercells (GRAd-COV2)Phase 2/3
Inactivated virus16162Day 0 + 14i.m.CoronaVac (Sinovac)Phase 4*
vaccines2Day 0 + 21i.m.Sinopharm/WIBP-CorVPhase 3*
2Day 0 + 28i.m.Institute of Medical Biology (verocells)Phase 3
2Day 0 + 21i.m.Research Institute for Biological Safety Problems (QazCovid-in)Phase 3
2Day 0 + 14i.m.Bharat Biotech(BBV152)Phase 3
2Day 0 + 28i.m.Shenzhen Kangtai Biological Products (Verocell)Phase 3
2Day 0 + 21i.m.Valneva, National Institute for Health Research, United Kingdom (VLA2001)Phase 3
2Day 0 + 21i.m.Erciyes University and the health instutes of turkey (TUSEB) (TURKOCAV)Phase 3
2Day 0 + 14i.m.Shifa Pharmed Industrial CoPhase 2/3
DNA vaccines10102Day 0 + 21i.m.Inovio Pharmaceuticals (INO-4800+electroporation)Phase 2/3
2Day 0 + 14i.m.AnGes + TakaraBio + Osaka University (AG0301-COVID19)Phase 2/3
3Day 0 + 28+ 56i.d.Zydus Cadila (nCovvaccine)Phase 3
Protein subunit32 vaccines312Day 0 + 21i.m.Novavax (NVX-CoV2373)Phase 3
2–3Day 0 + 28or Day 0 + 28 + 56i.m.Anhui Zhifei Longco (ZF2001-Recombinant SARS-CoV-2 Vaccine)Phase 3
2Day 0 + 21i.m.Sanofi Pasteur + GSK (VAT00002)Phase 3
2Day 0 + 21i.m.Clover Biopharmaceuticals Inc./GSK/Dynavax (SCB-2019 + AS03 or CpG 1018 adjuvant plus)Phase 2/3
2Day 0 + 28i.m.Instituto Finlay de Vacunas (FINLAY-FR-2 anti-SARS-CoV-2 Vaccine)Phase 3
2Day 0 + 21i.m.Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”(EpiVacCorona)Phase 3
30 + 14 + 28 or Day 0 + 28 + 56i.m.Center for Genetic Engineering and Biotechnology (CIGB-66)Phase 3
Virus like particle vaccines552Day 0 + 21i.m.Medicago Inc. (CoVLP)Phase 2/3

As of 3 June 2021, WHO has assessed that it meets the necessary criteria for safety and efficacy against COVID-19. %: clinical pass rate